Health-Related Quality of Life in Patients Poststroke: Dapsone Versus Placebo
Journal of Pharmacy Technology, 06/26/2012
Clinical Article
Cruz–Cruz C et al. – Stroke–Specific Quality of Life (SSQOL) was slightly better for patients who received dapsone, showing a possible improvement in their functional level. More prospective, randomized, and placebo–controlled studies with a larger number of patients are needed to confirm these results.
Methods- This was an observational pilot study of 21 patients who randomly received dapsone or placebo during the acute phase of a stroke.
- HRQOL was evaluated with the Stroke–Specific Quality of Life (SSQOL) questionnaire 6 months after the stroke.
- There was no significant difference in the total SSQOL score 6 months after a stroke between patients who received dapsone or placebo (3.41 vs 3.19; p=0.434).
- Patients who received dapsone had higher mean values for 9 of the 12 domains of the SSQOL than patients who received placebo.
- However, the difference was not statistically significant.
- The highest score for the patients who received dapsone was in the self–care domain.
- Overall SSQOL scores were lower in women than in men (p<0.01).
